Trials / Completed
CompletedNCT02305888
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
Safety of LEO 43204 0.018%, 0.037% and 0.1% for Actinic Keratosis Applied Once Daily for Three Consecutive Days on Face/Chest, Scalp and Trunk/Extremities, Respectively
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 189 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the trial is to investigate the Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 43204 | Treatment of actinic keratosis |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-07-01
- Completion
- 2015-08-01
- First posted
- 2014-12-03
- Last updated
- 2025-03-10
- Results posted
- 2019-03-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02305888. Inclusion in this directory is not an endorsement.